source
- Detalimogene Voraplasmid Achieves 54% Complete Response in BCG-Unresponsive Bladder CancerA clinical study of detalimogene voraplasmid reported a 54% complete response rate in patients with heavily pretreated, BCG‑unresponsive non‑muscle‑invasive bladder cancer that also had carcinoma i…
- Prevention and personalized skin care highlighted as future direction for melanoma oncodermatologyDr. Beth McLellan, a dermatologist, emphasizes that preventing radiation-induced skin damage is becoming a central focus in melanoma care. She also points out the need for equitable access to scal…